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Abstract
Background: Cell-based approaches towards restoration of prolapsed or degenerated intervertebral discs are
hampered by a lack of measures for safe administration and placement of cell suspensions within a treated disc. In
order to overcome these risks, a serum albumin-based hydrogel has been developed that polymerizes after
injection and anchors the administered cell suspension within the tissue.
Methods: A hydrogel composed of chemically activated albumin crosslinked by polyethylene glycol spacers was
produced. The visco-elastic gel properties were determined by rheological measurement. Human intervertebral disc
cells were cultured in vitro and in vivo in the hydrogel and their phenotype was tested by reverse-transcriptase
polymerase chain reaction. Matrix production and deposition was monitored by immuno-histology and by
biochemical analysis of collagen and glycosaminoglycan deposition. Species specific in situ hybridization was
performed to discriminate between cells of human and murine origin in xenotransplants.
Results: The reproducibility of the gel formation process could be demonstrated. The visco-elastic properties were
not influenced by storage of gel components. In vitro and in vivo (subcutaneous implants in mice) evidence is
presented for cellular differentiation and matrix deposition within the hydrogel for human intervertebral disc cells
even for donor cells that have been expanded in primary monolayer culture, stored in liquid nitrogen and re-
activated in secondary monolayer culture. Upon injection into the animals, gels formed spheres that lasted for the
duration of the experiments (14 days). The expression of cartilage- and disc-specific mRNAs was maintained in
hydrogels in vitro and in vivo, demonstrating the maintenance of a stable specific cellular phenotype, compared to
monolayer cells. Significantly higher levels of hyaluronan synthase isozymes-2 and -3 mRNA suggest cell
functionalities towards those needed for the support of the regeneration of the intervertebral disc. Moreover,
mouse implanted hydrogels accumulated 5 times more glycosaminoglycans and 50 times more collagen than the
in vitro cultured gels, the latter instead releasing equivalent quantities of glycosaminoglycans and collagen into the
culture medium. Matrix deposition could be specified by immunohistology for collagen types I and II, and
aggrecan and was found only in areas where predominantly cells of human origin were detected by species
specific in situ hybridization.
Conclusions: The data demonstrate that the hydrogels form stable implants capable to contain a specifically
functional cell population within a physiological environment.
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Biological regeneration of degenerated or traumatically
damaged intervertebral discs is a desirable goal, and in
the meantime an experimental focus of regenerative
medicine. In recent time, the re-injection into the
damaged disc of autologous disc cells harvested from
prolapses has been even performed in clinical trials
[1,2]. While data from such trials are emerging and sug-
gest at least partial clinical success, the procedure is
technically not satisfying yet. The injection of a liquid
suspension of cells into the disc tissue is not safe
enough without any measures to warrant the cells to
remain within the disc and not be ejected during initial
loading of the disc upon patient motion. Beyond this
safety aspect, the introduction of fresh cells may not
deliver success without simultaneously restoring the
nutritional requirements and the moderation or preven-
tion of inflammatory insults.
This present situation led several research groups to
consider hydrogels as a means to anchor cells in situ,
with the specific advantage that hydrogels might improve
the nutritional situation of a disc with respect to its water
content and the additional mechanical benefits of
rebuilding disc height and resistance to compression.
Two main strategies are imaged in literature: the surgical
implantation of a preformed implant (derived from cell-
free applications of hydrogels), and the injection of in
situ polymerizing formulations. The present situation is
reviewed in [3,4]. The structural basis for cell-supple-
mented hydrogels span across a remarkably long list of
molecular elements, including mammalian components
such as gelatin, chondroitin sulfate, hyaluronan, collagen,
plant polymers such as alginate, and synthetic polymers
such as polyethylene glycol, poly glycolic acid, and poly-
lactic acid or synthetic peptides. The crosslinking is
achieved by redox reactions (thiols), condensations (poly-
acrylates), or complex formation (alginate, peptides).
Some of those reactions are designed to exclude cellular
components from untoward inclusion into the reaction
cascade, thus avoiding toxic interactions; others are
balanced to minimize reactions that include cell surface
components, without being strictly selective. Cell survival
has been reported to be good to excellent, with most of
the reports initially relying on in vitro observations. From
those, a limited number has already been applied in
animal experiments, either in ectopic or intradiscal
administrations, with so far none reported to generate
local or systemic adverse reactions.
Within this broader context, we also developed a hydro-
gel to be injected as a fluid and to polymerize in situ. The
hydrogel is based on maleinimide-activated human serum
albumin and cross-links chemically by dithiol-polyethylene
glycol after mixing in a dual chamber syringe system
equipped with an interrupted-helical mixing chamber. The
hydrogel is enhanced with hyaluronan (HA) and adjusted
to a visco-elastic stage that allows the gel to creep rather
than build up significant local pressure, thus intended to
anchor cells within the defect compartment but not to re-
build disc volume. The hydrogel displays anti-angiogenic
properties in cell culture and in chorioallantois membrane
tests [5]. Those properties are considered to be key ele-
ments for disc regeneration since recently published data
underscore the negative effects of capillary ingrowth into
inflamed disc tissues [6-9]. The high molecular weight
crosslinked HA (Visiol
®, TBS Chemedica, Munich) itself is
passively interwoven with the albumin polymer since it
does not participate in the polymerization reaction. HA is
included in the recipe because of its well-described chon-
dro-protective, anti-inflammatory and biomechanical ben-
efits (for review, see [10]). Numerous other groups are
therefore currently also considering to apply HA in tissue
engineering of cartilaginous implants, alone or in combi-
nation with other materials, and in various stages of tech-
nical development [11-23].
Here we present first experimental evidence for the
hydrogel to be a suitable carrier for anchoring of disc
cells in an ectopic animal model. The hydrogel stabilizes
a chondrogenic phenotype of the cells, and facilitates
deposition of a cartilagenous extracellular matrix.
Methods
Animals
Subcutaneous implantation of the human preparation
was performed in a double-homozygous severe com-
bined immunodeficient (SCID) hairless outbred model
(Crl:SHO-Prkdc
scidHr
hr mice; Charles River Laboratories;
Sulzberg, Germany). The animal experiment was
approved by the Committee on Animal Care of the
State of Baden-Wuerttemberg (Germany).
Hydrogel preparation
Activated human maleolyl-albumin, hyaluronan and cell
culture medium without supplements and without serum
were used as basis for the albumin gel. Cross-linking was
achieved through a specific thio-polyethylene glycol (SH-
PEG, Rapp Polymere GmbH; Tuebingen, Germany) spacer
via Michael reaction of a maleolyl-group to a SH-group, as
described before [24] (pending patents number: PCT/
EP2008/005643, DPMA 10 2008 008 071.3).
For the production of maleolyl-albumin, 250 mg of
human serum albumin (Sigma-Aldrich; Steinheim,
Germany) were dissolved in 5 ml 1 M sodium borate
(Sigma-Aldrich). Afterwards 75 μl2 6 0m Mm a l e o l y l - b-
alanine in PBS/sodium borate (1:1) were added and
incubated for 90 min at room temperature. 106 mg
3-maleimidopropionic acid N-hydroxysuccinimide ester
(Obiter Research; Urbana, USA) were dissolved in
950 μl dimethylformamide. 500 μl of this solution were
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another 60 min. at room temperature. Afterwards
500 μl 3 M sodium acetate (Sigma-Aldrich) were added
and dialysed against phosphate buffered saline (PBS) for
1 h on ice three times. The dialysate was concentrated
to 3.5 ml by ultrafiltration (YM-3 membrane, Millipore;
Billerica, USA) and stored at -80°C.
To prepare 2 ml of hydrogel solution, 140 μl maleolyl-
albumin (43 mM), 1,060 μl cell culture medium and
400 μl high molecular weight hyaluronan (20 mg/ml, Vis-
iol; TRB Chemedica AG, Munich, Germany) were mixed
and incubated for 5 min. at room temperature. The
remaining 400 μl were reserved for the cell suspension.
The crosslinker solution comprised of 500 μlS H - P E G
(10,000 g/mol, 15 mM SH-groups) in 0.1 mM HCl, to
achieve a 1:1 ratio of maleolyl-groups to SH-groups when
being mixed with the hydrogel/disc cell solution. The gel
mixtures were submitted to a DIN/ISO 10993-4, -5, 10,
-11 biocompatibility testing (including gels prepared from
human albumin and of the test species mouse, rabbit, rat,
and guinea pig) by BIOSERV Analytik & Medizinprodukte
GmbH (Rostock, Germany) and passed successfully.
Rheological measurement of the visco-elastic properties
of the hydrogel and effect of storage of gel components
on the gelation process
All gel experiments were performed using a dual chamber
syringe system, with a 2-ml chamber filled with the
human disc cells suspended in culture medium plus high
molecular weight hyaluronan and the polymerization
agent maleimide-activated albumin, the other chamber
filled with the chemical crosslinker SH-PEG, as described
before [5,24].
To examine the visco-elastic properties of the hydrogels
and the effect of storage of gel components on the gelation
process rheological measurements were performed with a
Kinexus Pro rheometer (Malvern Instruments GmbH;
Herrenberg, Germany). Per analysis day the instrument
performance was checked before the measurement proce-
dure using calibration oil as a standard (PRA Coating
Technology; Hampton, UK). The two gel components
were mixed and injected onto the bottom plate of the
rheometer using a dual-chamber applicator syringe as
described in [24] and in the introduction. After automati-
cally adjusting the upper plate (1 Pa, plane configuration,
diameter 20 mm, spacing 0.6 mm) a ring envelope was
mounted around the piston to prevent water evaporation
during the experiment. The measurements started
approximately 30 sec. after gel mixture. The experimental
conditions for detection of gel formation were: tempera-
ture 37°C, shear strain 0.05%, shear stress 1 Pa, oscillation
frequency 1 Hz. The gelation process was monitored for a
period of 20 min. The electronic system continuously
detected and stored the storage modulus (G’ in Pa) and
the loss modulus (G’’ in Pa) with a frequency of 1 Hz. The
pressure of the upper plate on the gel was set to 1 Pa and
was automatically controlled during the process of
gelation.
Human tissue harvest
For the SCID mouse experiment human intervertebral
disc (IVD) tissues were harvested from six patients during
spinal fusion surgery. The donors were between 18 and
61 years old, two of them were female and four were male.
For the in vitro experiment, the IVD tissues were har-
vested from 2 patients undergoing nucleotomie after disc
herniation (male, 37 years; female, 32 years) and 2 patients
undergoing spinal fusion surgery (male, 46 years; female,
46 years).
Due to the nature of the surgical procedures, a clear dis-
tinction between annulus and nucleus pulposus tissue
could not always be made. Therefore, we aimed to collect
unspecified IVD cells rather than distinct populations. All
human tissues were obtained from the BG Trauma Center
in Tuebingen (Germany). The studies were approved by
the local ethics committee and informed consent was
obtained from all individuals participating in the study.
The sterile tissue was placed into culture medium and
instantly transported to the tissue culture facility.
Cell culture
Human IVD cell isolation and culture
Tissue samples were washed twice in PBS (BioWhittaker;
Verviers, Belgium) and then minced by scalpels. Extracel-
lular matrix was enzymatically degraded overnight by
incubation in DMEM high glucose medium (Invitrogen;
Karlsruhe, Germany) containing 0.375 mg/ml collagenase
B (Roche; Mannheim, Germany), 0.05 mg/ml hyaluroni-
dase (Serva; Heidelberg, Germany) and 5% human serum
at 37°C. Isolated disc cells were filtered through a 100-
μm cell strainer to remove undigested tissue fragments
and extracellular matrix debris. After centrifugation, the
cells were resuspended in DMEM/Ham’s- F 1 2c e l lc u l -
ture medium supplemented with 5% human serum (Cen-
tre for Clinical Transfusion Medicine, University of
Tuebingen, Germany), 150 μM ascorbic acid-2-phos-
phate, 100 U/ml penicillin, 100 μg/ml streptomycin and
plated in 75 cm
2 cell culture flasks at an initial density of
0.5 × 10
6 cells in a humidified atmosphere (95% air, 5%
CO2). The cells were harvested at 80 - 90% confluence
by trypsin-EDTA (BioWhittaker) treatment, washed, cen-
trifuged, the cell pellet resuspended in serum-free med-
ium, and the cell number determined (P0 culture). For
the in vitro experiment, the cells were use directly for
subsequent passage 1 (P1) cultivation either in monolayer
or embedded in the hydrogel. For the in vivo experiment
the P0 cells were stored above liquid nitrogen until
further use.
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To compare the behavior of the disc cells in the hydro-
gels and in monolayer culture, 0.5 × 10
6 cells/500 μl
hydrogel were cultured in one well of a 24-well plate. In
parallel, 0.17 × 10
6 cells were seeded in 25 cm
2 cell cul-
ture flasks. Cultures were harvested at day 4, 7, and 14
and used for gene expression analysis.
In vivo experiment
The frozen cells from all six primary cultures were simul-
taneously re-activated prior to the experiment by seeding
them once more into 75 cm
2 cell culture flasks at 2 × 10
6
cells/flask and expanding into confluence in the presence
of 10% human serum and 1:1000 ITS liquid media supple-
ment (insulin, transferrin, sodium selenite). They were
harvested simultaneously by trypsinization (P1 cells). The
harvested human cells were suspended in the implantation
culture medium (consisting of a proprietary mixture of
good manufacturing practice (GMP) grade phenol red -
free culture medium, supplemented with 5% human
serum), then mixed with the hydrogel solution (5 × 10
6/ml
gel solution) and transferred into the 2-mlcompartment of
a dual chamber syringe. The second 0.5-ml-compartment
was filled with SHPEG solution. The syringe was main-
tained at 4°C until use.
Surgical implantation into and recovery from mice
Using the dual-chamber syringe, 1.25 × 10
6 IVD disc cells
resuspended in 250 μl hydrogel were injected subcuta-
neously in the back of double-homozygous SCID hairless
outbred model (Crl:SHO-Prkdc
scidHr
hr mice; Charles
River Laboratories; Sulzberg, Germany). Polymerization of
the hydrogel was achieved in situ. Two weeks later, the
hydrogels were explanted, lysed for gene expression analy-
sis or embedded in Tissue Tek, snap-frozen in liquid
nitrogen and stored. As a control, hydrogels containing
IVD cells from the same patients were cultured in vitro
(250 μl in a 24-well) for two weeks (n = 6 patients).
Histology
The frozen tissue samples were sliced by a cryotome to pre-
pare 50 μm sections, and stained with haematoxylin-eosin
(HE). The sections were analyzed by immunohistology with
antibodies against collagen type I (Anti-human collagen
type I 63170, lot 1467 K, MP Biomedicals; LLC, Solon,
Ohio, USA), collagen type II (clone II-II6B3; 1 μg/ml; [25],
and aggrecan (SM1353, Lot 040308, Acris Antibodies
GmbH; Herford, Germany). The collagen type II antibody
was obtained from the Developmental Studies Hybridoma
Bank maintained by the Department of Pharmacology and
Molecular Sciences, Johns Hopkins University School of
Medicine, Baltimore, MD 21205, and the Department of
Biological Sciences, University of Iowa, Iowa City, IA
52242, under contract NO1-HD-2-3144. Secondary
antibodies were Cy3-conjugated IgG antibodies from Dia-
nova (Hamburg, Germany). Control sections were prepared
without primary antibody. The stained sections were ana-
lyzed by normal light or fluorescence microscopy (Axio-
phot, Zeiss; Jena, Germany). Photography was performed
with an electronic camera (Axiocam, Zeiss).
In situ hybridization
For the discrimination between cells of murine and human
origin species specific in situ hybridization was done.
Digoxigenin (DIG)-labeled mouse specific SINE/B1 and
SINE/B2 and human specific Alu probes were generated
as described previously [26]. Sections were washed three
times in PBS containing 0.1% Tween at room temperature
and then treated with 50 μg/ml proteinase K (Fermentas,
Germany) in PBS containing 0.1% Tween for 10 min at
37°C. After washing in PBS, sections were treated with
0.25% acetic acid containing 0.1 M triethanolamine (pH
8.0) for 10 min. and then pre-hybridized for 1 h at 42°C in
hybridization buffer containing 4 × saline-sodium citrate
(SSC), 50% deionized formamide, 1 × Denhardts solution,
5% dextrane sulfate and 100 μg/ml salmon sperm DNA.
Hybridization buffer was replaced by fresh buffer contain-
ing 0.2 ng/ml DIG-labeled probe (either human Alu or
mouse SINE B1/B2) before target DNA and probe were
denatured for 5 min. at 95°C. Hybridization was carried
out for 16 h at 42°C in a wet chamber. Slides were washed
twice in SSC for 5 min at RT and twice for 10 min. at
42°C in 0.1% SSC. Signals were detected using anti-DIG
alkaline phosphatase conjugated Fab fragments (Roche,
Germany) and nitroblue tetrazolium (NBT)/5-bromo-4-
chloro-3-indolyl phosphate (BCIP) (Roche, Germany) as a
substrate.
Biochemistry
To analyze the extracellular matrix in the hydrogels the
glycosaminoglycan (GAG) and collagen content was deter-
mined in the digested hydrogels and in the supernatants of
the in vitro controls. Hydrogels were digested with 1 mg/
ml papain (Sigma-Aldrich) in 0.1 M Naacetate, 0.01 M L-
cysteine, 0.05 M Na
2-EDTA, and 0.2 M NaCl (pH 6.0) at
60°C overnight. Culture supernatants were used without
digestion. The GAG content was measured by the restric-
tive version of the dimethylmethyleneblue (DMB) assay,
including guanidinium hydrochloride in the protocol [27]
and using chondroitin-4-sulfate (Sigma-Aldrich) as a stan-
dard. Proteoglycan content was expressed as μg GAG per
complete hydrogel (with a hydrogel volume of approx.
0.25 ml). Total collagen content was measured by the
hydroxyproline assay based upon alkaline hydrolysis and
reaction with chloramine-T and dimethylbenzamidine
using gelatine as a standard [28]; the resulting values were
expressed as μg collagen per complete hydrogel.
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To recover the cells for gene expression analysis from
monolayers, an aliquot of the initial cell suspension after
detachment of the cells was used and the cell pellet
lysed in RNeasy lysis-buffer (Qiagen; Hilden, Germany).
In vitro cultured hydrogels were digested with protei-
nase K (3 mg/ml; Sigma-Aldrich) for about 10 min. at
37°C, the digest was centrifuged and the cell pellet lysed
in RNeasy lysis-buffer [24]. The gel pieces retrieved
f r o mt h em i c ew e r es n a p - f r o z e ni nl i q u i dn i t r o g e n ,
ground in a mortar, then dissolved in RLT-buffer for
RNA extraction. Total RNA was extracted using the
RNeasy mini kit plus DNase I digestion according to the
manufacturer’s instructions (Qiagen). Complementary
DNA (cDNA) was obtained by reverse transcription of
total RNA using the Reverse Transcriptase Core kit
(Eurogentec; Cologne, Germany) with EuroScript reverse
transcriptase (Moloney Murine leukemia virus reverse
transcriptase, 50 U/μl) and oligo-dT primers. Reverse
transcription was performed in a total volume of 50 μl
at 48°C for 30 min. in a thermocycler (Whatman Biome-
tra; Goettingen, Germany).
Gene expression was analyzed by quantitative real-time
PCR using an Applied Biosystems 7500 Fast Real-Time
PCR System. The qPCR mastermix plus for SYBR green I
(low ROX) kit from Eurogentec was used. Approximately
1 μg of cDNA, 100 - 300 mM primers and 2 × reaction
buffer were pipetted to a total volume of 25 μl. Primers
defining exon-intron boundary spanning segments were
newly designed with the primer express 2.0 software
(Applied Biosciences; Darmstadt, Germany), except pri-
mers for type II collagen (COL2A1) [29], and were
obtained from BIOTEZ. Sequences of all primers used are
summarized in Table 1. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a reference gene.
The PCR reaction was started with an initial enzyme acti-
vation step at 95°C for 10 min (hot start), followed by 40
cycles of 95°C for 15 sec, 60°C for 30 sec, and 72°C for 30
sec. After the last cycle a dissociation curve was generated.
Threshold cycles (Ct values) were determined using
Sequence Detection System software (Applied Biosys-
tems). Ct value of the reference gene was subtracted from
the Ct value of the gene of interest (dCt) and the relative
expression was expressed as 2
-dCt. Median expression was
calculated and is displayed in box plots relative to the
median expression of the initial cell population. The boxes
represent 25%/75% percentiles, mean (dotted line) and
median (solid line) values.
Statistics
Statistical analysis was performed using SigmaStat 3.0
(SPSS Science Software; Erkrath, Germany). Probability
values p below 0.05 were considered to be significant.
Specific details of the applied statistical functions are
given in the figures respectively the corresponding figure
legends. In general, both median and mean are documen-
ted, considering the typically high variability of human
cell cultures.
Results
The underlying philosophy of the experiments was to
provide a continuous data set for the behavior of the
intervertebral disc cells related to the hydrogel environ-
ment, as displayed during the cell expansion, after harvest
into secondary culture as a monolayer or as an in vitro
3D (hydrogel) culture, and finally isolated in the ectopic
environment (within the hydrogel) of the subcutaneous
location in the mouse.
Rheological measurements
Rheological measurements were performed with nascent
gel formulations produced out of the dual chamber syringe
as described previously [24]. One measurement is exem-
plified in Figure 1. The gelation process of the gel is com-
pleted after approximately 2 - 3 minutes; thereafter the
visco-elastic properties of the hydrogel remain nearly
constant.
A total of 24 finished products were analyzed (Table 2).
Thirteen measurements were performed with freshly pre-
pared hydrogel components, five measurements were
performed after storage gel components at 4°C for 24 h
and six measurements were performed after storing the
gel components at 4°C for 72 h. The hydrogel production
process could be successfully standardized; thus hydro-
gels with reproducible visco-elastic properties can be
produced. There was no significant difference in storage
modulus G’ (measurements 1-3) and loss modulus G”
(measurements 4-6) between the three time points
(Table 2). Initial storage of the liquid gel precursors for
72 h does not alter the visco-elastic properties of the
polymerized hydrogel. This storage time was chosen to
simulate the necessary transportation of the hydrogel
components to the user after preparation of the gel solu-
tion/cells mix.
In vitro reference culture
In an in vitro reference culture the alterations in gene
expression of the matrix genes collagen type I, type II and
aggrecan were analyzed at different time points during the
culture of disc cells in monolayer and hydrogel cultures.
This data set expression was compared to the expression
data of the initial cell population (P0) used for the subcul-
ture (Figure 2). Collagen type I expression was almost
unchanged over time and independent from culture type.
Collagen type II expression decreased in monolayer cul-
tures, at the end of the 14 days monolayer culture the
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expression in the P0 cells. In contrast, in hydrogels the
expression at all three time points was higher than in the
P0 cells (median: 2 - 5-fold; mean: 1,7 - 11-fold). Although
these differences were not statistically significant due to
restricted number of patients (n = 4) and high individual
variations a clear tendency was visible: the hydrogel cul-
ture improved the collagen type II expression compared to
the monolayer (median: 10-fold, mean: 200-fold higher at
day 14). Aggrecan expression was less effected by culture
type. Nonetheless the same tendency for improved expres-
sion in hydrogels can be seen as for collagen type II
mRNA expression.
Mouse subcutaneous implants and in vitro cultured
hydrogels
The subcutaneous implantation into mice was intended
to extend the in vitro data towards an in vivo applica-
tion. In preliminary experiments, we found that gels
without cells were completely resorbed within 8-12
weeks post implantation in SCID mice (data not
shown). In order to achieve rapid accumulation of extra-
cellular matrix, we decided to inoculate the hydrogels
with a relatively high cell density. At the same time, this
high density would give us pharmacological information
on overdosing effects concerning the viability of cells in
the gel under the presumed restrictive nutritional
Table 1 PCR primers
Gene Forward/reverse Product Length Accession #
GAPDH
[a] AGAAAAACCTGCCAAATATGATGAC 126 NM_002046.3
TGGGTGTCGCTGTTGAAGTC
COL1A2
[a] GCTGGCAGCCAGTTTGAATATAAT 78 NM_000089.3
CAGGCGCATGAAGGCAAGT
COL2A1
[b] AGAGGTATAATGATAAGGATGTGTGGAAG 83 NM_001844.3
GTCGTCGCAGAGGACAGTCC
ACAN
[a] TGCATTCCACGAAGCTAACCTT 84 NM_013227
GACGCCTCGCCTTCTTGAA
HAS2
[a] GACCCGTTGGAGCAAGTCCTA 151 NM_005328.2
ACCCCGGTAGAAGAGCTGGAT
HAS3
[a] CGGTGGCTCAACCAGCAA 151 AF234839
GTATAACCGTGGCAATGAGGAAGA
SOX9
[a] ATCCAAGCGCATTACCCACT 132 NM_000346.3
CGATTCTCCATCATCCTCCAC
a Primers designed in-house using Primer Express 2.0 software
b [29]
Figure 1 Gelation process of the hydrogel. The graph depicts the gelation process of the hydrogel separated into two phases, the gelation
and the curing phase. The two gel components were mixed and injected onto the bottom plate of the rheometer using a dual-chamber
applicator syringe. After adjusting the upper plate, the measurement started approximately 30 sec after gel mixture. The experimental conditions
of the gel formation were: temperature 37°C, shear strain 0.05%, shear stress 1 Pa, oscillation frequency 1 Hz. Storage modulus G’, representing
the elastic component of the gel, and loss modulus G”, representing the viscous component of the gel, were calculated every third second. The
gelation is completed after approximately 2-3 minutes; thereafter the visco-elastic properties of the hydrogel are constant.
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unlimited supply in culture medium. The entire in vivo
experiment was performed with cryo-conserved, in sec-
ondary culture expanded disc cells from six different
patients, similar as planned to the future therapeutical
use.
Upon injection, the gel polymerized instantly and pro-
duced approximately 0.25-ml globules that remained
stable and visible during the entire 14 days of incubation
in the animal (Figure 3A). For comparison, cell-laden
hydrogels were maintained in vitro in culture for the
same time period.
At harvest, the implants presented as a separate entity
within the animals. The opaque gels could be peeled out
of the subcutis without any damage (Figure 3B). In con-
trast to their initial plasticity, the gels were solid to the
grip and displayed some elasticity and structural
stability.
Concerning the hydrogel itself, histological inspection
revealed a rather homogenous distribution of the disc
cells within the hydrogel (Figure 4A-C). There were no
obvious regions with particular features such as higher
densities of viable cells at the edge or the centre. To
verify the presence and the distribution of human cells
in the transplants a species specific genomic hybridiza-
tion was performed. It was possible to discriminate
between cells of human origin and cells of murine ori-
gin. Mouse cells are predominantly found at the edge of
the xenotransplant (Figure 4E) (corresponding with the
collagen type I staining); human cells are distributed
evenly within the transplant (Figure 4D), confirming the
above notion of the initial rather homogenous cell dis-
tribution. It appears that few cells with positive mouse
Alu hybridization are also present within the hydrogel
(Figure 4E). These might be false positive signals, as the
probes to mouse Alu sequences tend to weakly bind to
human Alu sequences. Since there are fewer mouse
sequences than human Alu, the detection reaction with
Figure 2 mRNA expression profiles of human disc cell preparations cultured in vitro in monolayer or hydrogel. P1 cells were harvested
at days 4, 7, and 14 and the expression of collagen type I (COL1), collagen type II (COL2), and aggrecan (ACAN) was analyzed. Expression values
of the P1 cultures are expressed relative to the median expression of the cells at the end of the expansion phase (P0) (median because the data
are not normally distributed). Boxes represent 25%/75% percentiles, mean values (dotted line) and median values (solid line).
Table 2 Effect of pre-gelation storage time at 4°C on the
visco-elastic properties of the hydrogel
storage time 0 h 24 h 72 h
measurement # 1 2 3
number of hydrogels 13 5 6
mean G’[Pa] 265.2 377.8 187.7
standard deviation 158.1 78.1 156.4
measurement # 4 5 6
number of hydrogels 13 5 6
mean G’’[Pa] 39.7 28.9 25.0
standard deviation 22.6 10.3 9.8
Storage modules G’ and loss modules G” were determined from hydrogels
produced immediately after preparing the gel components (0 h), and after
storing the liquid gel components for 24 h or 72 h at 4°C. Mean value
comparison using ANOVA showed no difference of storage modules between
measurements # 1 - 3 and no difference of loss modules between
measurements # 4 - 6 (P < 0.05)
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bound probes per nucleus in mouse cells. In this case,
the unspecific binding on human cells may also appear
and cause the present false positive signals on some
cells.
The inner portions of the gel were positive for col-
lagen type II and aggrecan immunostaining with the
stain being either evenly distributed or clustered; col-
lagen type I was found at the edges, and to a much les-
ser degree, in the centre of the gels. The accumulation
of collagen type I at the edges of the in vivo transplants
correlates with the appearance of a fibroblastic cell ring
at the border of the gels, which could be seen in the in
vitro cultured gels (data not shown).
In contrast to these staining patterns from the subcuta-
neous hydrogels, the in vitro cultured hydrogels displayed
only very poor immunostaining for any antigen (data not
shown, see also biochemical analysis in Figures 5 and 6).
Upon macroscopic inspection, the hydrogels maintained
in tissue culture for 14 days remained clear and soft with
high plasticity, quite in contrast to the gels harvested
from the mice. The results of the bulk biochemical
Figure 3 Injection and harvest of cell-loaded hydrogels. A: Injection from dual syringe and 1.3 mm Ø needle. The hydrogel (arrow)
polymerizes upon injection and forms a stable subcutaneous protrusion. B: Hydrogel (arrow) at harvest. Note the absence of vascular and
connective tissue ingrowth.
Figure 4 Immunohistochemistry staining and species specific genomic in situ hybridization of an implanted hydrogel upon harvest. A:
Detection of collagen type I; B: collagen type II; C: aggrecan by immunohistochemistry. The blue dots are the DAPI stained nuclei. Note the
even distribution of the nuclei across the samples, except for the edge in A. Species specific in situ hybridization discriminates between cells of
human origin (D) and cells of murine origin (E). Mouse cells are predominantly found at the edge of the xenotransplant, human cells are
distributed evenly within the transplant.
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hydrogels contained more than five times less glycosami-
noglycans (GAG) than implanted gels (Figure 5). The
collagen deposition in implanted gels was even 50-fold
higher as in cultured gels (Figure 6). On the other hand,
when the GAG and collagen content of the culture med-
ium was taken into consideration, the total GAG and col-
lagen output of the cultured cells was seemingly rather
equal to that of the implanted cells (Figure 5 und6). In
vitro cultured cells produced slightly but significantly
more GAG than the subcutaneous cultured cells (1.2-
fold), conversely collagen accumulation was significantly
higher in in vivo hydrogels (1.4-fold). Taken together, the
entire process of matrix deposition in vivo could be con-
sidered to be more efficient towards formation of a func-
tional tissue whereas in vitro conditions seemingly
delayed that process.
At time of harvest, the deposition of ECM within the
hydrogels was accompanied by a still active gene expres-
sion in the human cells, analyzed by RT-PCR for a
number cartilage- and disc-specific factors including col-
lagen types I, II, aggrecan, hyaluronan synthases-2 and
-3 (HAS2, HAS3), and SOX9 as a chondrocytic/disc
cells key transcription factor (Figure 7). The median
expression was compared to the expression levels of the
initial cell population (P1) used for the production of
the cell/hydrogel constructs (P2). As seen in the in vitro
experiment, no significant changes in the transcription
of genes coding for the matrix molecules collagen type I
(COL1), type II (COL2), and aggrecan (ACAN) could be
detected. Although both in vitro and in vivo hydrogels
showed by trend higher expression levels for COL2 and
ACAN, this effect was not statistically significant.
Hydrogel culture had an extensive effect of the tran-
scription of the hyaluronan-synthase genes and of the
transcription factor SOX9. HAS2 and HAS3 expression
was up-regulated to 4-5 orders of magnitudes in hydro-
gels cultures compared to the initial P1 cell population.
Expression of both genes was slightly higher in in vitro
hydrogels than in in vivo hydrogels (1.2-fold for HAS2
and 5-fold for HAS3), an effect being statistically signifi-
cant for HAS2. Compared to P1 cells mRNA for SOX9
w a sf o u n d8 0t i m e sh i g h e ri nin vitro hydrogels and
about 160 times higher in in vivo transplants. As SOX9
expression accompanies chondrocytes and disc cells dif-
ferentiation and cartilage/disc specific matrix produc-
tion, the higher expression in hydrogels refers to a more
differentiated phenotype compared the P1 cells.
Discussion
The present study generated data that support the idea
of disc repair through the administration of interverteb-
ral disc cells harvested from a disc prolaps and captured
within an injectable hydrogel. In vitro and in vivo data
point to a sustainable functionality of phenotypic disc
cells within the hydrogel. Even though the present study
did not investigate cell viability in particular, the gene
Figure 5 Glycosaminoglycan production from cells of in vitro
maintained and of in vivo implanted hydrogels. Note that most
of the glycosaminoglycans (GAG) from the in vitro cultures were
found in the culture medium (middle bar). Mean values (n = 6) and
standard deviation are shown. In vitro gel: GAG content of the in
vitro cultured hydrogel; in vitro gel + medium: GAG content of the
in vitro cultured hydrogel plus the GAG released into the combined
medium supernatant from two weeks of culture; in vivo: GAG
content of the in vivo implanted hydrogel. Statistic: paired t-test
comparing the in vitro group (gel + medium) and the in vivo group,
*=p < 0.05.
Figure 6 Cumulated collagen production from cells of in vitro
maintained and of in vivo implanted hydrogels. Note that most
of the collagens from the in vitro cultures were found in the culture
medium (middle bar). Mean values (n = 6) and standard deviations
are shown. In vitro gel: collagen content of the in vitro cultured
hydrogel; in vitro gel + medium: collagen content of the in vitro
cultured hydrogel plus the collagen released into the combined
medium supernatant from two weeks of culture; in vivo: collagen
content of the in vivo implanted hydrogel. Statistic: paired t-test
comparing the in vitro group (gel + medium) and the in vivo group,
*=p < 0.05.
Benz et al. BMC Musculoskeletal Disorders 2012, 13:54
http://www.biomedcentral.com/1471-2474/13/54
Page 9 of 13expression data indicate high viability in the present set-
tings. Earlier work provided evidence that the viability
of a number of cell types embedded into the hydrogel,
including disc cells, is greater than 90% [24]. In particu-
lar the rapid deposition of cartilagenous ECM and the
significant levels of hyaluronan synthase isozymes-2 and
-3, and SOX9 suggest cell functionalities towards those
needed for the support of damaged intervertebral disc
cores (the original nucleus pulposus). The reproducibil-
ity of the particular visco-elastic properties (rheological
data) encourages administration of the gel mixture
within the confinements of the damaged disc. The bio-
mechanical properties of the hydrogel in intervertebral
discs remain to be determined in specific studies to fol-
low and have been in part presented by Beger [30].
Hydrogels are rapidly gaining attention as highly versa-
tile carriers of bioactive compounds and cells in tissue
engineering approaches [31-33]. We decided on a hydrogel
formulation that is governed by aspects of drug safety and
clinically established subcomponents. Contrary to many
approaches, we refrained from choosing a base compound
(such as collagen), that in itself may exert cell regulative
properties towards chondrocyte-like cell types as they are
found in intervertebral discs. This decision is based,
among other considerations, on the well-known fact that
chondrocytes and nucleus pulposus cells differentiate best
in agarose, a compound that exerts no metabolic effect
towards the cells and possesses a maximum of retentive
properties towards newly synthesized ECM components,
keeping the ECM in the vicinity of the cells [34,35]. Algi-
nate is similar to agarose, in this aspect [36,37]. Serum
albumin can be purchased as prescription drug. The cho-
sen cross-linker, polyethylene glycol, has a long-standing
history as a pharmaceutical additive and, as plasma expan-
der, a proven history of non-toxicity. Albumin is readily
degraded in vivo, with no toxic or otherwise critical inter-
mediates or end products being generated in this process.
Furthermore, in contrast to ester-based biopolymers,
degradation of albumin does not set free acidic compo-
nents. Thus a shift to lower pH is not expected during
degradation of the hydrogel. The chemical polymerization
reactions, starting from the maleimide activation of albu-
min and ending in the dual chamber application modality,
possess no pharmaceutical problems, neither.
Figure 7 mRNA expression profiles of the human disc cells in vitro and in vivo. The expression of collagen type I (COL1), collagen type II
(COL2), aggrecan (ACAN), hyaluronan-synthase-2 (HAS2), hyaluronan-synthase-3 (HAS3) and SRY (sex determining region Y)-box 9 (SOX9) was
analyzed in P2 cells hydrogels cultured for two weeks in vitro or implanted in mice for two weeks and compared to the median expression of
the P1 cells (median because not all data were normally distributed). Statistic: One Way repeated Measures Analysis of Variance was performed if
the data of all groups were normally distributed, if not, Friedman Repeated Measures Analysis of Variance on Ranks was done. * = p < 0.05.
Boxes represent 25%/75% percentiles, mean values (dotted line) and median values (solid line).
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device, several components simultaneously, the thera-
peutic combination of cells, scaffold and regeneration-
promoting substances (such as the hyaluronan applied
here) was demonstrated in the presented animal experi-
ment. No animal displayed any sign of distress, and
recovery from anesthesia was speedy because of the
short time needed for the injection. The injected mix-
ture polymerized in situ a n dd i dn o td i s s i p a t eu p o n
injection. There was a distinct border between the host
tissue and the implant that could not be surmounted by
invasive cell types of the animals’ subcutis, just as pub-
lished recently [5]. A subsequent histological examina-
tion of the in vivo maintained hydrogels revealed that
the hydrogel prevented tissue ingrowth in part by its
anti-angiogenic properties. This effect was then experi-
mentally explored in various test systems and has been
reported elsewhere [5].
One surprising key finding of these experiments was
t h ep r e s e n c eo fab a l a n c e dp r i m a r yG A Ga n dc o l l a g e n
biosynthesis by the cells for the cultured hydrogel as
well as for the implanted hydrogels even though under
the in vitro conditions, there was much less deposition
of GAG and collagen within the gel structure. Regarding
mRNA expression among the three groups of cells,
P1cells, P2 in vitro hydrogel, and P2 in vivo hydrogel,
there was a difference in favor of higher transcriptional
activities in the hydrogels, but especially the difference
between in in vitro and in vivo hydrogels resulted in
only marginal differences from a functional standpoint
in that both conditions led to approximately identical
protein output by the cells. Baseline metabolic condi-
tions may not be responsible for that effect since
GAPDH expression levels were quite similar under all
three conditions at time of harvest (data not shown).
What differed, however, was the effective deposition of
the produced ECM molecules within the hydrogels in
vitro and in vivo.
Thus, the resulting difference in matrix deposition
may have not been due to overall metabolic conditions
but rather related to specific effects, such as differential
matrix metalloprotease activities in vivo versus in vitro
or the encapsulation by murine tissue. The higher
deposition of GAG and collagen molecules in implanted
gels may also arise from biomechanical stimulation of
the construct in the in vivo situation. Additionally, the
effect may be facilitated by the hypoxic conditions in a
non-vascularised subcutaneous implant in mice [38,39].
The differential deposition of collagen type I and II
within the in vivo incubated gels may represent another
hint for specific processing of such matrix molecules or
of spontaneous differential evolvement of cell types
(chondrocytes/nucleus pulposus cells and fibrochondro-
cytes). These speculations need further investigations,
though. The additional high levels of SOX9 message
also differentiate cells from unspecific connective tissue
cells and underscore their chondrogenic roots.
The pronounced expression of hyaluronan synthases
supports the function of the hydrogel/cell mixture as
disc regenerating element. HAS2 is the main producer
of hyaluronan in chondrocytes, has been reported to be
highly expressed in the intact nucleus pulposus [40,41].
HA is known to significantly contribute to osmotic pres-
sure by locally binding large molar quantities of water
[42]. The effect is enlarged by albumin, as in synovial
fluid [43]. It has been investigated in many physiological
contexts, including for example kidney, where HA sup-
ports water retentive activity [44], abdominal wall mus-
culature, where HA supports the maintenance of the
interstitial pressure [45], and in growth plates, where it
facilitates in volume expansion of the hypertrophic cells
[46,47], to name some functions. HAS activity may
therefore be chiefly responsible for the maintenance of
the high hydrostatic pressure of a healthy disc.
Conclusions
T h ep r e s e n ts t u d yp r o v i d e se x p e r i m e n t a le v i d e n c et o
s u p p o r tt h ei d e ao fd i s cr e p a i rb yi n t e r v e r t e b r a ld i s c
cells harvested from a disc prolaps and applied together
with an injectable hydrogel. In vitro and in vivo data
suggest that human disc cells even after a cryopreserva-
tion step are maintained in a functionally mature stage
for at least two weeks when maintained in the hydrogel.
Moreover, the molecular data derived from cells in
hydrogel in vitro and in vivo corroborate the hypothesis
that in vitro cultivation of cells in the hydrogel has
some relevance for the development of such implants
for clinical applications as well. In particular the rapid
deposition of cartilagenous ECM and the significant
levels of hyaluronan synthase isozymes-2 and -3 of the
propagated disc cells suggest functionalities needed for
the support of damaged intervertebral discs. In conti-
nuation of these experiments, a large animal disc injury
model for intervention in sheep based on hydrogel/cell
composites application has already been completed. The
data are currently evaluated, with early assessment indi-
cating that upon further refinement the present
approach will probably become suitable for disc repair
in the near future.
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